Android app on Google Play

Halozyme Therapeutics (HALO) Falls Short of Q4 Views

March 11, 2011 7:32 AM EST Send to a Friend
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.

You May Also Be Interested In

Related Categories


Add Your Comment